Barclays raises Ionis stock price target on Tryngolza opportunity

📌 Key Takeaways

• Barclays raised Ionis Pharmaceuticals' stock price target.
• The decision is based on the potential of the drug Tryngolza.
• The specific reasons for the increase remain unspecified.
• The update reflects confidence in Ionis's pipeline.

🏷️ Themes

Stocks, Pharmaceuticals, Investment

📚 Related People & Topics

Barclays

British multinational banking and financial services company

Barclays PLC (, occasionally ) is a British multinational universal bank, headquartered in London, England. Barclays operates as five divisions: the UK Consumer Bank, UK Corporate Bank, Private Bank and Wealth Management (PBWM), Investment Bank, and the US Consumer Bank. Barclays traces its origins ...

View Profile → Wikipedia ↗

Medication

Substance used to diagnose, cure, treat, or prevent disease

Medication (also called medicament, medicine, pharmaceutical drug, medicinal product, medicinal drug, or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for co...

View Profile → Wikipedia ↗

Olezarsen

Medication

Olezarsen, sold under the brand name Tryngolza, is a medication used in the treatment of familial chylomicronemia syndrome. It is given by injection under the skin. Olezarsen is an apolipoprotein C-III-directed antisense oligonucleotide.

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Barclays:

Mentioned Entities

Barclays

British multinational banking and financial services company

Ionis

Topics referred to by the same term

Medication

Substance used to diagnose, cure, treat, or prevent disease

Olezarsen

Medication

Source

investing.com